Healthcare entity

RAS

Company

regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Brian Wolpin, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention RAS, all published on August 27, 2026.

Last mentioned: Aug 27, 2026

Entity pulse

Recent coverage · RAS

1 story
8 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about RAS

regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Brian Wolpin, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention RAS, all published on August 27, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering RAS. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. FDA Approval

    FDA approves daraxonrasib (Rasonque) for metastatic pancreatic cancer, six months ahead of the regulatory deadline.

  2. Breakthrough Therapy Designation

    FDA grants daraxonrasib Breakthrough Therapy designation for advanced pancreatic cancer.

Stories mentioning RAS 1

RAS is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.